Lifeline Biotechnologies Announces Start of China Market Introduction of Proprietary MastaScope Diagnostic Product Following Granting of Chinese SDA Registration Number.

RENO, Nev. -- Lifeline Biotechnologies, Inc. (PINK:LBTN) today announced that the company has been granted a registration number by the Chinese SDA, for the company's MastaScope(TM) product. This SDA registration number is comparable to the CE mark and FDA 510K approvals that have already been granted for the product. The SDA registration enables the company to begin market introduction of the MastaScope in China.

Jim Holmes, chairman of Lifeline Technologies, made the announcement adding: "We have been working diligently for almost a year now on obtaining approval and are delighted that we are now able to commence our marketing effort in this country in earnest." Holmes noted that according to the Surveillance and Risk Assessment Division, CCDP, Health Canada, the incidence of breast cancer among Chinese women was 32 women per 100,000 population in 1993. "That was 12 years ago and other reports, such as that found in a People's Daily Online report from March of 2002, have indicated that the incidence of breast cancer among Chinese women was rising at a rate of at least 27 percent over the past decade with some 40 percent of Chinese women diagnosed with breast cancer dying within five years because the cancer is already advanced at the time of diagnosis. We believe as the MastaScope can help in the early detection and diagnosis of cancer and other abnormalities of the breast."

As a result of being granted the Chinese SDA, Lifeline reports that a significant meeting among prominent Chinese and Japanese physicians and surgeons to demonstrate and train them in the attributes and use of the MastaScope in the early detection of breast cancer is scheduled for later this month. "This demonstration and training session will be held at one of Beijing's major hospitals and we believe it will be attended by physicians representing eight to 10 Chinese and Japanese hospitals," Holmes said.

Last September Lifeline announced that it entered into a four-year contract with International Medical Consulting Group (IMCG) of Dallas, Texas, for its Chinese company, Shanghai Science Medical Equipment, Ltd. to distribute Lifeline's proprietary MastaScope Mammary Ductoscopy System in the People's Republic of China.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.